miRNA-31 Improves Cognition and Abolishes Amyloid-β Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease

Alzheimer's disease (AD) is the most common form of dementia worldwide, characterized by progressive memory impairment, behavioral changes, and, ultimately, loss of consciousness and death. Recently, microRNA (miRNA) dysfunction has been associated with increased production and impaired clearan...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Teresa Barros-Viegas (Author), Vítor Carmona (Author), Elisabete Ferreiro (Author), Joana Guedes (Author), Ana Maria Cardoso (Author), Pedro Cunha (Author), Luís Pereira de Almeida (Author), Catarina Resende de Oliveira (Author), João Pedro de Magalhães (Author), João Peça (Author), Ana Luísa Cardoso (Author)
Format: Book
Published: Elsevier, 2020-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0a6fe9c2a19a4a2f9dc6dd4e1645a878
042 |a dc 
100 1 0 |a Ana Teresa Barros-Viegas  |e author 
700 1 0 |a Vítor Carmona  |e author 
700 1 0 |a Elisabete Ferreiro  |e author 
700 1 0 |a Joana Guedes  |e author 
700 1 0 |a Ana Maria Cardoso  |e author 
700 1 0 |a Pedro Cunha  |e author 
700 1 0 |a Luís Pereira de Almeida  |e author 
700 1 0 |a Catarina Resende de Oliveira  |e author 
700 1 0 |a João Pedro de Magalhães  |e author 
700 1 0 |a João Peça  |e author 
700 1 0 |a Ana Luísa Cardoso  |e author 
245 0 0 |a miRNA-31 Improves Cognition and Abolishes Amyloid-β Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease 
260 |b Elsevier,   |c 2020-03-01T00:00:00Z. 
500 |a 2162-2531 
500 |a 10.1016/j.omtn.2020.01.010 
520 |a Alzheimer's disease (AD) is the most common form of dementia worldwide, characterized by progressive memory impairment, behavioral changes, and, ultimately, loss of consciousness and death. Recently, microRNA (miRNA) dysfunction has been associated with increased production and impaired clearance of amyloid-β (Aβ) peptides, whose accumulation is one of the most well-known pathophysiological markers of this disease. In this study, we identified several miRNAs capable of targeting key proteins of the amyloidogenic pathway. The expression of one of these miRNAs, miR-31, previously found to be decreased in AD patients, was able to simultaneously reduce the levels of APP and Bace1 mRNA in the hippocampus of 17-month-old AD triple-transgenic (3xTg-AD) female mice, leading to a significant improvement of memory deficits and a reduction in anxiety and cognitive inflexibility. In addition, lentiviral-mediated miR-31 expression significantly ameliorated AD neuropathology in this model, drastically reducing Aβ deposition in both the hippocampus and subiculum. Furthermore, the increase of miR-31 levels was enough to reduce the accumulation of glutamate vesicles in the hippocampus to levels found in non-transgenic age-matched animals. Overall, our results suggest that miR-31-mediated modulation of APP and BACE1 can become a therapeutic option in the treatment of AD. Keywords: Alzheimer's disease, miR-31, gene therapy, lentiviral vector, APP, BACE1, amyloid-β peptide, cognitive function, memory 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Molecular Therapy: Nucleic Acids, Vol 19, Iss , Pp 1219-1236 (2020) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2162253120300457 
787 0 |n https://doaj.org/toc/2162-2531 
856 4 1 |u https://doaj.org/article/0a6fe9c2a19a4a2f9dc6dd4e1645a878  |z Connect to this object online.